1
by McCrory, Douglas C.
Published 2013
Agency for Healthcare Research and Quality

2
by McCrory, Douglas C.
Published 2013
Agency for Healthcare Research and Quality

3
Published 2014
Canadian Agency for Drugs and Technologies in Health
... drug therapies for pulmonary arterial hypertension (PAH), and will examine their cost-effectiveness...

4
by Tran, Khai
Published 2015
Canadian Agency for Drugs and Technologies in Health
... of pulmonary arterial hypertension (PAH) in adults...

5
Published 2015
Canadian Agency for Drugs and Technologies in Health
...Pulmonary arterial hypertension (PAH) is a chronic and progressive disease characterized...

6
Published 2014
Canadian Agency for Drugs and Technologies in Health
... drug therapies for pulmonary arterial hypertension (PAH), and will examine their cost-effectiveness...

7
by Tran, Khai
Published 2015
Canadian Agency for Drugs and Technologies in Health
... of pulmonary arterial hypertension (PAH) in adults...

8
Published 2015
Canadian Agency for Drugs and Technologies in Health
...Pulmonary arterial hypertension (PAH) is a chronic and progressive disease characterized...

9
by Trembath, Richard C.
Published 2014
Henry Stewart Talks
Subjects: ...Pulmonary Artery / pathology...

10
by Southgate, Laura
Published 2022
MDPI - Multidisciplinary Digital Publishing Institute
Subjects: ...pulmonary arterial hypertension...

11
Published 2009
Humana
... disorders characterized by scarring or fibrosis of the lungs. In Pulmonary Arterial Hypertension...

12
Published 2015
Canadian Agency for Drugs and Technologies in Health
Subjects: ...Pulmonary Artery / physiopathology...

13
Published 2015
Canadian Agency for Drugs and Technologies in Health
...Pulmonary arterial hypertension (PAH; also classified as Group 1 pulmonary hypertension [PH]) is a...

14
Published 2015
Canadian Agency for Drugs and Technologies in Health
...Pulmonary arterial hypertension (PAH; also classified as Group 1 pulmonary hypertension [PH]) is a...

15
by Balk, Ethan
Published 2008
AHRQ Technology Assessment Program
...-based Practice Center (Tufts EPC) conduct a technology assessment report on pulmonary artery catheter...

16
Published 2017
Canadian Agency for Drugs and Technologies in Health
...Selexipag (Uptravi) for pulmonary arterial hypertension (WHO class II and III)...

17
Published 2017
Canadian Agency for Drugs and Technologies in Health
...Selexipag (Uptravi) for pulmonary arterial hypertension (WHO class II and III)...

18
Published 2016
Canadian Agency for Drugs and Technologies in Health
...-term treatment of idiopathic pulmonary arterial hypertension (PAH), heritable HPAH, PAH associated...

19
Published 2016
Canadian Agency for Drugs and Technologies in Health
...-term treatment of idiopathic pulmonary arterial hypertension (PAH), heritable HPAH, PAH associated...

20
by Karmouty-Quintana, Harry
Published 2019
Frontiers Media SA
Subjects: ...pulmonary arterial hypertension...